AD 121

Drug Profile

AD 121

Alternative Names: AD121; PW 9101

Latest Information Update: 18 Feb 2004

Price : $50

At a glance

  • Originator Penwest Pharmaceuticals; Sosei R&D
  • Developer Sosei R&D
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 02 Feb 2004 Discontinued - Phase-I/II for Rheumatoid arthritis in United Kingdom (PO)
  • 29 Nov 2000 Phase-I/II clinical trials for Rheumatoid arthritis in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top